1. China Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Shenzhen Neptunus Bioengineering Co., Ltd. Class A

Shenzhen Neptunus Bioengineering Co., Ltd. Class A

SSZSE:000078
1.33
CNY
+0.02
(+1.53%)
-0.31EPS
3.39BMarket Cap
Shenzhen Neptunus Bioengineering Co., Ltd. Class A
SZSE:000078
(Shenzhen Stock Exchange)

Recent

price

1.33

P/E

ratio

- -

div

yld

14.35%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.45
3.25
3.93
4.49
5.36
15.19
6.13
9.42
14.51
15.68
15.26
15.62
14.39
13.84
11.52
10.14
8.89
Revenue per Share
0.03
0.03
0.04
0.07
0.01
0.65
0.19
0.24
0.17
0.08
-0.11
0.04
-0.39
-0.64
-0.45
-0.21
-0.3
Basic EPS, GAAP
-0.04
-0.18
-0.15
-0.23
-0.19
-0.11
-0.8
-1.02
-0.51
0.79
0.57
0.28
-0.06
-0.2
-0.02
-0.01
- -
Free Cash Flow per Basic Share
0.06
0.07
0.09
0.09
0.12
0.39
0.09
0.06
0.41
0.51
0.29
0.22
0.25
0.21
0.19
0.2
0.19
Dividend per Share
0.45
0.49
0.52
0.83
0.79
0.96
2.03
2.08
2.26
2.26
2.14
2.12
1.71
1.09
0.68
0.47
0.39
Book Value per Share
0.32
0.34
0.35
0.64
0.59
0.73
1.71
0.59
0.65
0.92
1.09
1.08
0.88
0.61
0.36
0.21
0.13
Tangible Book Value per Share
1,632
1,631
1,632
1,780
1,830
732
2,221
2,648
2,646
2,646
2,623
2,628
2,630
2,631
2,631
2,631
2,632
Basic Weighted Avg Shares
3,999
5,305
6,418
7,993
9,802
11,118
13,606
24,940
38,381
41,493
40,022
41,054
37,835
36,419
30,317
26,668
23,390
Sales/Revenue/Turnover
4.16
4.28
3.59
3.41
3.73
4.39
5.97
6.43
5.1
5.58
4.57
3.83
2.67
2.43
1.75
2.13
1.57
Operating Margin (%)
53
53
61
70
87
80
75
103
131
152
194
269
276
284
245
215
- -
Depreciation Expense
47
53
59
117
24
475
418
639
448
206
-289
93
-1,027
-1,690
-1,193
-563
-785
Net Income, GAAP
48.68
38.1
6.57
34.17
46.64
17.6
23.7
28.78
30.82
41.25
115.44
55.26
- -
- -
- -
- -
- -
Effective Tax Rate (%)
1.17
0.99
0.92
1.46
0.24
4.27
3.08
2.56
1.17
0.5
-0.72
0.23
-2.71
-4.64
-3.94
-2.11
-3.36
Profit Margin (%)
-223
-15
-73
509
154
740
3,696
2,350
3,058
2,742
1,677
1,855
1,831
1,081
256
36
-340
Working Capital
62
- -
- -
- -
- -
- -
24
1,703
3,374
1,359
357
377
400
320
330
435
361
LT Debt
903
971
1,057
1,888
1,783
2,143
5,878
6,470
7,158
7,851
7,490
7,308
6,112
4,217
2,844
2,177
1,854
Total Equity
2.11
1.84
2.56
1.58
1.88
10.81
7.43
8.41
4.27
2.62
-0.23
1.19
- -
- -
- -
- -
- -
Return on Invested Capital (%)
4.06
4.58
5.52
2.96
2.09
13.5
7.51
6.82
4.91
2.98
-3.19
1.53
- -
- -
- -
- -
- -
Return on Capital (%)
6.81
6.85
7.22
9.9
1.61
29.28
11.67
11.75
7.79
3.37
-4.76
1.59
-19.54
-43.92
-49.74
-37.26
-55.22
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
11,264
11,184
9,825
LT Borrowings
362
298
293
LT Finance Leases
74
69
68
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,631
2,631
2,631
Market Capitalization
9,104
8,262
3,394

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
23,738
23,199
21,193
Cash, Cash Equivalents & STI
3,098
3,592
2,412
Accounts Receivable, Net
13,199
13,009
11,498
Inventories
3,204
2,987
2,936
Total Current Liabilities
23,702
23,189
21,533
Payables & Accruals
- -
- -
- -
ST Debt
11,264
11,184
9,825
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.42%
-21.16%
-23.46%
Free Cash Flow
176.05%
-17.84%
-49.63%
Net Income, GAAP
-163.35%
-270.15%
-52.82%
Sales/Revenue/Turnover
12.64%
-7.56%
-12.04%
Total Cash Common Dividend
43.31%
-6.78%
1.29%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,088
8,544
7,921
5,765
30,317
2025
7,376
6,936
- -
5,155
26,668
2026
5,945
5,354
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
-0.47
-0.45
2025
0.01
- -
- -
-0.22
-0.21
2026
0.01
-0.08
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.06
0.04
0.05
0.19
2025
0.04
0.04
- -
0.07
0.2
2026
0.04
0.04
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) engages in the research, development, production, and sales of Chinese patent medicines, infusion products, and western medicine preparations primarily in China; oryzanol tablets, chlorpheniramine tablets, chlorpheniramine maleate tablets, estazolam tablets, rifampicin capsules, antiviral and anti-infective drugs, cardiovascular medications, and immune regulators; drugs targeting malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, infectious diseases, respiratory system diseases, and digestive system diseases; distribution of drugs, medical devices, and medical supplies; value-added services for hospitals, medical institutions, drug retailers, and distributors. Founded in 1989 and headquartered in Shenzhen, China, the company operates a vertically integrated model covering pharmaceutical commerce, industry, and R&D, with a focus on domestic markets supplemented by international exports to regions including Southeast Asia and Africa. Recent developments include receipt of clinical trial approval in March 2025 for NEP018 tablets, a novel small molecule kinase inhibitor for gastrointestinal tumors developed by its wholly-owned Shenzhen Neptunus Pharmaceutical Technology Research Institute Co., Ltd., alongside continued R&D investment at approximately 8.5% of revenue and termination of certain cooperation agreements with Neptunus Group and Silk Spinning Group in June 2025.